Advisory Committee for Pharmaceutical Science; Notice of Meeting, 18407 [05-7129]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 68 / Monday, April 11, 2005 / Notices
Dated: April 1, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–7130 Filed 4–8–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Advisory Committee for
Pharmaceutical Science; Notice of
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Advisory
Committee for Pharmaceutical Science.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on May 3 and 4, 2005, from 8:30
a.m. to 5 p.m.
Location: Food and Drug
Administration, Center for Drug
Evaluation and Research Advisory
Committee Conference Room, rm. 1066,
5630 Fishers Lane, Rockville, MD.
Contact Person: Hilda Scharen, Center
for Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, 301–827–7001, e-mail:
scharenh@cder.fda.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572) in the
Washington, DC area), code
3014512539. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: On May 3, 2005, the
committee will: (1) Receive an update
from the Clinical Pharmacology
Subcommittee and (2) discuss and
provide comments on the general topic
of establishing drug release or
dissolution specifications. On May 4,
2005, the committee will: (1) Receive an
update on current activities of the
Parametric Tolerance Interval Test
Workgroup, (2) discuss and provide
comments on the general topic of
considerations for assessment of
pharmaceutical equivalence and
product design, and (3) discuss criteria
for establishing a working group for
review and assessment of Office of
VerDate jul<14>2003
17:45 Apr 08, 2005
Jkt 205001
Pharmaceutical Science research
programs.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by April 25, 2005. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. each day. Time allotted
for each presentation may be limited.
Those desiring to make formal oral
presentations should notify the contact
person before April 25, 2005, and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Hilda
Scharen at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 1, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–7129 Filed 4–8–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Meeting of the Advisory
Committee on Organ Transplantation
Health Resources and Services
Administration, HHS.
SUMMARY: Pursuant to Pub. L. 92–463,
the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the eighth meeting of
the Advisory Committee on Organ
Transplantation (ACOT), Department of
Health and Human Services (HHS). The
meeting will be held from
approximately 9 a.m. to 5:30 p.m. on
May 9, 2005, and from 9 a.m. to 3 p.m.
on May 10, 2005, at the Rockville
DoubleTree Hotel, 1750 Rockville Pike,
Rockville, Maryland 20852. The meeting
AGENCY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
18407
will be open to the public; however,
seating is limited and pre-registration is
encouraged (see below).
SUPPLEMENTARY INFORMATION: Under the
authority of 42 U.S.C. Section 217a,
Section 222 of the Public Health Service
Act, as amended, and 42 CFR 121.12
(2000), ACOT was established to assist
the Secretary in enhancing organ
donation, ensuring that the system of
organ transplantation is grounded in the
best available medical science, and
assuring the public that the system is as
effective and equitable as possible, and,
thereby, increasing public confidence in
the integrity and effectiveness of the
transplantation system. ACOT is
composed of up to 25 members,
including the Chair. Members are
serving as Special Government
Employees and have diverse
backgrounds in fields such as organ
donation, health care public policy,
transplantation medicine and surgery,
critical care medicine and other medical
specialties involved in the identification
and referral of donors, non-physician
transplant professions, nursing,
epidemiology, immunology, law and
bioethics, behavioral sciences,
economics and statistics, as well as
representatives of transplant candidates,
transplant recipients, organ donors, and
family members.
ACOT will hear presentations from
staff of the Centers for Medicare and
Medicaid Services (CMS) on the CMS
Organ Procurement Organization Notice
of Proposed Rulemaking and the
Transplant Center Notice of Proposed
Rulemaking. The presentations may
include a discussion and summary of
the comments received during the 60day public comment period which
began February 4.
The draft meeting agenda will be
available on April 15 on the
Department’s donation Web site at http:/
/www.organdonor.gov/acot.html.
A registration form will be available
on March 15 on the Department’s
donation Web site at https://
www.organdonor.gov/acot.html. The
completed registration form should be
submitted by facsimile to Professional
and Scientific Associates (PSA), the
logistical support contractor for the
meeting, at fax number (703) 234–1701.
Individuals without access to the
Internet who wish to register may call
Bryan Slattery with PSA at (703) 234–
1734. Individuals who plan to attend
the meeting and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the ACOT Executive
Director, Thomas E. Balbier, Jr., in
advance of the meeting. Mr. Balbier may
E:\FR\FM\11APN1.SGM
11APN1
]]>Agencies
[Federal Register Volume 70, Number 68 (Monday, April 11, 2005)]
[Notices]
[Page 18407]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-7129]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee for Pharmaceutical Science; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Advisory Committee for Pharmaceutical Science.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on May 3 and 4, 2005, from
8:30 a.m. to 5 p.m.
Location: Food and Drug Administration, Center for Drug Evaluation
and Research Advisory Committee Conference Room, rm. 1066, 5630 Fishers
Lane, Rockville, MD.
Contact Person: Hilda Scharen, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857,
301-827-7001, e-mail: scharenh@cder.fda.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572) in the Washington, DC
area), code 3014512539. Please call the Information Line for up-to-date
information on this meeting.
Agenda: On May 3, 2005, the committee will: (1) Receive an update
from the Clinical Pharmacology Subcommittee and (2) discuss and provide
comments on the general topic of establishing drug release or
dissolution specifications. On May 4, 2005, the committee will: (1)
Receive an update on current activities of the Parametric Tolerance
Interval Test Workgroup, (2) discuss and provide comments on the
general topic of considerations for assessment of pharmaceutical
equivalence and product design, and (3) discuss criteria for
establishing a working group for review and assessment of Office of
Pharmaceutical Science research programs.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by April 25,
2005. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. each day. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before April 25, 2005,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Hilda Scharen at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 1, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-7129 Filed 4-8-05; 8:45 am]
BILLING CODE 4160-01-S
